Cargando…

Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes

AIMS/HYPOTHESIS: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Sarah J., Rodriguez-Calvo, Teresa, Gerling, Ivan C., Mathews, Clayton E., Kaddis, John S., Russell, Mark A., Zeissler, Marie, Leete, Pia, Krogvold, Lars, Dahl-Jørgensen, Knut, von Herrath, Matthias, Pugliese, Alberto, Atkinson, Mark A., Morgan, Noel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/
https://www.ncbi.nlm.nih.gov/pubmed/27506584
http://dx.doi.org/10.1007/s00125-016-4067-4
_version_ 1782456657088872448
author Richardson, Sarah J.
Rodriguez-Calvo, Teresa
Gerling, Ivan C.
Mathews, Clayton E.
Kaddis, John S.
Russell, Mark A.
Zeissler, Marie
Leete, Pia
Krogvold, Lars
Dahl-Jørgensen, Knut
von Herrath, Matthias
Pugliese, Alberto
Atkinson, Mark A.
Morgan, Noel G.
author_facet Richardson, Sarah J.
Rodriguez-Calvo, Teresa
Gerling, Ivan C.
Mathews, Clayton E.
Kaddis, John S.
Russell, Mark A.
Zeissler, Marie
Leete, Pia
Krogvold, Lars
Dahl-Jørgensen, Knut
von Herrath, Matthias
Pugliese, Alberto
Atkinson, Mark A.
Morgan, Noel G.
author_sort Richardson, Sarah J.
collection PubMed
description AIMS/HYPOTHESIS: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully characterised and was recently challenged as artefactual. Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes. The principal aims were to consider whether HLA class I hyperexpression is artefactual and, if not, to determine the factors driving it. METHODS: Pancreas samples from type 1 diabetes patients with residual insulin-containing islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain containing 5 (NLRC5) and islet hormones. RNA was extracted from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analysed using gene-expression arrays. RESULTS: Hyperexpression of HLA class I was observed in the insulin-containing islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels. The expression of β2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated. Both ‘classical’ HLA class I isoforms (i.e. HLA-ABC) as well as a ‘non-classical’ HLA molecule, HLA-F, were hyperexpressed in insulin-containing islets. This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5. However, it was strongly associated with increased STAT1 expression in all three cohorts. Islet hyperexpression of HLA class I molecules occurred in the insulin-containing islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter. CONCLUSIONS/INTERPRETATION: Islet cell HLA class I hyperexpression is not an artefact, but is a hallmark in the immunopathogenesis of type 1 diabetes. The response is closely associated with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-016-4067-4) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-5042874
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-50428742016-11-01 Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes Richardson, Sarah J. Rodriguez-Calvo, Teresa Gerling, Ivan C. Mathews, Clayton E. Kaddis, John S. Russell, Mark A. Zeissler, Marie Leete, Pia Krogvold, Lars Dahl-Jørgensen, Knut von Herrath, Matthias Pugliese, Alberto Atkinson, Mark A. Morgan, Noel G. Diabetologia Article AIMS/HYPOTHESIS: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully characterised and was recently challenged as artefactual. Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes. The principal aims were to consider whether HLA class I hyperexpression is artefactual and, if not, to determine the factors driving it. METHODS: Pancreas samples from type 1 diabetes patients with residual insulin-containing islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain containing 5 (NLRC5) and islet hormones. RNA was extracted from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analysed using gene-expression arrays. RESULTS: Hyperexpression of HLA class I was observed in the insulin-containing islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels. The expression of β2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated. Both ‘classical’ HLA class I isoforms (i.e. HLA-ABC) as well as a ‘non-classical’ HLA molecule, HLA-F, were hyperexpressed in insulin-containing islets. This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5. However, it was strongly associated with increased STAT1 expression in all three cohorts. Islet hyperexpression of HLA class I molecules occurred in the insulin-containing islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter. CONCLUSIONS/INTERPRETATION: Islet cell HLA class I hyperexpression is not an artefact, but is a hallmark in the immunopathogenesis of type 1 diabetes. The response is closely associated with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-016-4067-4) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2016-08-09 2016 /pmc/articles/PMC5042874/ /pubmed/27506584 http://dx.doi.org/10.1007/s00125-016-4067-4 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Richardson, Sarah J.
Rodriguez-Calvo, Teresa
Gerling, Ivan C.
Mathews, Clayton E.
Kaddis, John S.
Russell, Mark A.
Zeissler, Marie
Leete, Pia
Krogvold, Lars
Dahl-Jørgensen, Knut
von Herrath, Matthias
Pugliese, Alberto
Atkinson, Mark A.
Morgan, Noel G.
Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
title Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
title_full Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
title_fullStr Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
title_full_unstemmed Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
title_short Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
title_sort islet cell hyperexpression of hla class i antigens: a defining feature in type 1 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/
https://www.ncbi.nlm.nih.gov/pubmed/27506584
http://dx.doi.org/10.1007/s00125-016-4067-4
work_keys_str_mv AT richardsonsarahj isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT rodriguezcalvoteresa isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT gerlingivanc isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT mathewsclaytone isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT kaddisjohns isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT russellmarka isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT zeisslermarie isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT leetepia isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT krogvoldlars isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT dahljørgensenknut isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT vonherrathmatthias isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT pugliesealberto isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT atkinsonmarka isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes
AT morgannoelg isletcellhyperexpressionofhlaclassiantigensadefiningfeatureintype1diabetes